{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:04:44Z","timestamp":1790089484003,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Wuxi Taihu Lake Talent Plan, Supports for Leading Talents in Medical and Health Profession","award":["No. 202101"],"award-info":[{"award-number":["No. 202101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01939-x","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:38:13Z","timestamp":1763433493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The gut-bone axis in ankylosing spondylitis: mechanistic insights and the translational gap"],"prefix":"10.1007","volume":"26","author":[{"given":"Xuhong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueni","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1939_CR1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563\u201374. https:\/\/doi.org\/10.1056\/NEJMra1406182.","journal-title":"N Engl J Med."},{"key":"1939_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41584-020-0454-9","volume":"16","author":"E Gracey","year":"2020","unstructured":"Gracey E, Vereecke L, McGovern D, Fr\u00f6hling M, Schett G, Danese S, et al. Revisiting the gut\u2013joint axis: links between gut inflammation and spondyloarthritis. Nat Rev Rheumatol. 2020;16:415\u201333. https:\/\/doi.org\/10.1038\/s41584-020-0454-9.","journal-title":"Nat Rev Rheumatol"},{"key":"1939_CR3","doi-asserted-by":"publisher","unstructured":"Baeten D, De Keyser F, Mielants H, Veys EM, Elsevier BV. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2002;16:537\u201349. https:\/\/doi.org\/10.1053\/berh.2002.0249.","DOI":"10.1053\/berh.2002.0249"},{"key":"1939_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00281-021-00845-0","volume":"43","author":"Z Qaiyum","year":"2021","unstructured":"Qaiyum Z, Lim M, Inman RD. The gut-joint axis in spondyloarthritis: immunological, microbial, and clinical insights. Semin Immunopathol. 2021;43:173\u201392. https:\/\/doi.org\/10.1007\/s00281-021-00845-0.","journal-title":"Semin Immunopathol"},{"key":"1939_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3899\/jrheum.180135","volume":"94","author":"E Gilis","year":"2018","unstructured":"Gilis E, Mortier C, Venken K, Debusschere K, Vereecke L, Elewaut D. The role of the microbiome in gut and joint inflammation in psoriatic arthritis and spondyloarthritis. J Rheumatol. 2018;94:36\u20139. https:\/\/doi.org\/10.3899\/jrheum.180135.","journal-title":"J Rheumatol"},{"key":"1939_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jbspin.2016.02.017","volume":"83","author":"D Wendling","year":"2016","unstructured":"Wendling D. The gut in spondyloarthritis. Joint Bone Spine. 2016;83:401\u20135. https:\/\/doi.org\/10.1016\/j.jbspin.2016.02.017.","journal-title":"Joint Bone Spine"},{"key":"1939_CR7","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/rheumatology\/key001","volume":"57","author":"D Simone","year":"2018","unstructured":"Simone D, Al Mossawi MH, Bowness P. Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology. 2018;57:4\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/key001.","journal-title":"Rheumatology."},{"key":"1939_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11926-019-0856-3","volume":"21","author":"SJ Pedersen","year":"2019","unstructured":"Pedersen SJ, Maksymowych WP. The pathogenesis of ankylosing spondylitis: an update. Curr Rheumatol Rep. 2019;21:58. https:\/\/doi.org\/10.1007\/s11926-019-0856-3.","journal-title":"Curr Rheumatol Rep"},{"key":"1939_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Hermann K-GA, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73:817\u201323. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204248.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber S, Colombel J-F, Feagan BG, Reich K, Deodhar AA, McInnes IB, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78:473\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214273.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093233","author":"L Wang","year":"2023","unstructured":"Wang L, Wei Z, Pan F, Song C, Peng L, Yang Y, et al. Case report: fecal microbiota transplantation in refractory ankylosing spondylitis. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1093233.","journal-title":"Front Immunol"},{"key":"1939_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0016-5085(89)91557-6","volume":"96","author":"M De Vos","year":"1989","unstructured":"De Vos M, Cuvelier C, Mielants H, Veys E, Barbier F, Elewaut A. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology. 1989;96:339\u201344. https:\/\/doi.org\/10.1016\/0016-5085(89)91557-6.","journal-title":"Gastroenterology"},{"key":"1939_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111727","volume":"8","author":"J So","year":"2020","unstructured":"So J, Tam L-S. Gut microbiome and its interaction with immune system in spondyloarthritis. Microorganisms. 2020;8:1727. https:\/\/doi.org\/10.3390\/microorganisms8111727.","journal-title":"Microorganisms"},{"key":"1939_CR14","doi-asserted-by":"publisher","first-page":"1376525","DOI":"10.3389\/fcimb.2024.1376525","volume":"14","author":"Q-Y Su","year":"2024","unstructured":"Su Q-Y, Zhang Y, Qiao D, Song X, Shi Y, Wang Z, et al. Gut microbiota dysbiosis in ankylosing spondylitis: a systematic review and meta-analysis. Front Cell Infect Microbiol. 2024;14:1376525. https:\/\/doi.org\/10.3389\/fcimb.2024.1376525.","journal-title":"Front Cell Infect Microbiol"},{"key":"1939_CR15","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","volume":"180","author":"JD Taurog","year":"1994","unstructured":"Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fern\u00e1ndez-Sueiro JL, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 1994;180:2359\u201364. https:\/\/doi.org\/10.1084\/jem.180.6.2359.","journal-title":"J Exp Med"},{"key":"1939_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ibd.20040","volume":"13","author":"F Hoentjen","year":"2007","unstructured":"Hoentjen F, Tonkonogy SL, Qian B-F, Liu B, Dieleman LA, Sartor BR. CD4+ T lymphocytes mediate colitis in HLA-B27 transgenic rats monoassociated with nonpathogenic bacteroides vulgatus. Inflamm Bowel Dis. 2007;13:317\u201324. https:\/\/doi.org\/10.1002\/ibd.20040.","journal-title":"Inflamm Bowel Dis"},{"key":"1939_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1010572","author":"Z-Y Song","year":"2022","unstructured":"Song Z-Y, Yuan D, Zhang S-X. Role of the microbiome and its metabolites in ankylosing spondylitis. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.1010572.","journal-title":"Front Immunol"},{"key":"1939_CR18","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.2147\/JIR.S517979","volume":"18","author":"L Yang","year":"2025","unstructured":"Yang L, Wang K, Liu B, Chen T, Ma T, Cui Z, et al. Dysbiosis of gut microbiota in ankylosing spondylitis patients. JIR Dove Press. 2025;18:7841\u201354. https:\/\/doi.org\/10.2147\/JIR.S517979.","journal-title":"JIR Dove Press"},{"key":"1939_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11357-024-01451-2","volume":"47","author":"J Escalante","year":"2025","unstructured":"Escalante J, Artaiz O, Diwakarla S, McQuade RM. Leaky gut in systemic inflammation: exploring the link between gastrointestinal disorders and age-related diseases. Geroscience. 2025;47:1\u201322. https:\/\/doi.org\/10.1007\/s11357-024-01451-2.","journal-title":"Geroscience"},{"key":"1939_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.623874","author":"D Baeten","year":"2021","unstructured":"Baeten D, Adamopoulos IE. IL-23 inhibition in ankylosing spondylitis: where did it go wrong? Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2020.623874.","journal-title":"Front Immunol"},{"key":"1939_CR21","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","volume":"71","author":"X Huang","year":"2023","unstructured":"Huang X, Shentu H, He Y, Lai H, Xu C, Chen M, et al. Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. Immunol Res. 2023;71:505\u201315. https:\/\/doi.org\/10.1007\/s12026-023-09366-4.","journal-title":"Immunol Res"},{"key":"1939_CR22","doi-asserted-by":"publisher","unstructured":"Hou Y, Li J, Ying S, Multidisciplinary Digital Publishing Institute. Tryptophan metabolism and gut microbiota: a novel regulatory axis integrating the microbiome, immunity, and cancer. Metabolites. 2023;13:1166. https:\/\/doi.org\/10.3390\/metabo13111166.","DOI":"10.3390\/metabo13111166"},{"key":"1939_CR23","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.immuni.2013.08.003","volume":"39","author":"T Zelante","year":"2013","unstructured":"Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39:372\u201385. https:\/\/doi.org\/10.1016\/j.immuni.2013.08.003.","journal-title":"Immunity"},{"key":"1939_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nm.4102","volume":"22","author":"B Lamas","year":"2016","unstructured":"Lamas B, Richard ML, Leducq V, Pham H-P, Michel M-L, Da Costa G, et al. CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med. 2016;22:598\u2013605. https:\/\/doi.org\/10.1038\/nm.4102.","journal-title":"Nat Med"},{"key":"1939_CR25","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","volume":"74","author":"F Ciccia","year":"2015","unstructured":"Ciccia F, Guggino G, Rizzo A, Saieva L, Peralta S, Giardina A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:1739\u201347. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206323.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1172\/JCI33194","volume":"118","author":"K Sugimoto","year":"2008","unstructured":"Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest Am Soc Clinical Investig. 2008;118:534\u201344. https:\/\/doi.org\/10.1172\/JCI33194.","journal-title":"J Clin Invest Am. Soc. Clinical Investig."},{"key":"1939_CR27","doi-asserted-by":"publisher","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J, et al. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4\u2212CD8\u2212 entheseal resident T cells. Nat Med. 2012;18:1069\u201376. https:\/\/doi.org\/10.1038\/nm.2817.","DOI":"10.1038\/nm.2817"},{"key":"1939_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5950395","volume":"2017","author":"J-R Zhang","year":"2017","unstructured":"Zhang J-R, Pang D-D, Tong Q, Liu X, Su D-F, Dai S-M. Different modulatory effects of IL-17, IL-22, and IL-23 on osteoblast differentiation. Mediators Inflamm. 2017;2017:1\u201311. https:\/\/doi.org\/10.1155\/2017\/5950395.","journal-title":"Mediators Inflamm"},{"key":"1939_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.immuni.2011.11.011","volume":"36","author":"J Qiu","year":"2012","unstructured":"Qiu J, Heller JJ, Guo X, Chen ZE, Fish K, Fu Y-X, et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity. 2012;36:92\u2013104. https:\/\/doi.org\/10.1016\/j.immuni.2011.11.011.","journal-title":"Immunity"},{"key":"1939_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature06881","volume":"453","author":"M Veldhoen","year":"2008","unstructured":"Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld J-C, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453:106\u20139. https:\/\/doi.org\/10.1038\/nature06881.","journal-title":"Nature"},{"key":"1939_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/nature06880","volume":"453","author":"FJ Quintana","year":"2008","unstructured":"Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453:65\u201371. https:\/\/doi.org\/10.1038\/nature06880.","journal-title":"Nature"},{"key":"1939_CR32","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00296-024-05601-9","volume":"44","author":"M Ivanova","year":"2024","unstructured":"Ivanova M, Zimba O, Dimitrov I, Angelov AK, Georgiev T. Axial spondyloarthritis: an overview of the disease. Rheumatol Int. 2024;44:1607\u201319. https:\/\/doi.org\/10.1007\/s00296-024-05601-9.","journal-title":"Rheumatol Int"},{"key":"1939_CR33","doi-asserted-by":"publisher","unstructured":"International Genetics of Ankylosing Spondylitis Consortium (IGAS), Cortes A, Hadler J, Pointon JP, Robinson PC, Karaderi T, et al. Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. Nat Genet. 2013;45:730\u20138. https:\/\/doi.org\/10.1038\/ng.2667","DOI":"10.1038\/ng.2667"},{"key":"1939_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.614255","volume":"12","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, Watad A, Sharif K. Why inhibition of IL-23 lacked efficacy in ankylosing spondylitis. Front Immunol. 2021;12:614255. https:\/\/doi.org\/10.3389\/fimmu.2021.614255. (Bridgewood C.).","journal-title":"Front Immunol"},{"key":"1939_CR35","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","volume":"75","author":"E Gracey","year":"2016","unstructured":"Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, et al. IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis. 2016;75:2124\u201332. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208902.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR36","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2015;74:1373\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205253.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR37","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 2019;71:258\u201370. https:\/\/doi.org\/10.1002\/art.40728.","journal-title":"Arthritis Rheumatol"},{"key":"1939_CR38","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC-C, Sieper J, J\u00e4rvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77:1295\u2013302. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213328.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR39","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F, Bossuyt P, Colombel J-F, Danese S, et al. Risankizumab as induction therapy for crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399:2015\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(22)00467-6.","journal-title":"Lancet"},{"key":"1939_CR40","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","volume":"9","author":"MN van Tok","year":"2018","unstructured":"van Tok MN, Na S, Lao CR, Alvi M, Pots D, van de Sande MGH, et al. The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Front Immunol. 2018;9:1550. https:\/\/doi.org\/10.3389\/fimmu.2018.01550.","journal-title":"Front Immunol"},{"key":"1939_CR41","doi-asserted-by":"publisher","unstructured":"Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan A, et al. Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis. 2019;78:1559\u201365. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215210.","DOI":"10.1136\/annrheumdis-2019-215210"},{"key":"1939_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","volume":"405","author":"V Navarro-Comp\u00e1n","year":"2025","unstructured":"Navarro-Comp\u00e1n V, Sepriano A, Capelusnik D, Baraliakos X. Axial spondyloarthritis. Lancet. 2025;405:159\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(24)02263-3.","journal-title":"Lancet"},{"key":"1939_CR43","doi-asserted-by":"publisher","unstructured":"Huang J-X, Lee Y-H, Wei JC-C, Taylor & Francis. Ixekizumab for the treatment of ankylosing spondylitis. Expert Rev Clin Immunol. 2020;16:745\u201350. https:\/\/doi.org\/10.1080\/1744666X.2020.1803063.","DOI":"10.1080\/1744666X.2020.1803063"},{"key":"1939_CR44","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1505066.","journal-title":"N Engl J Med"},{"key":"1939_CR45","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/ajg.2016.298","volume":"111","author":"SR Targan","year":"2016","unstructured":"Targan SR, Feagan B, Vermeire S, Panaccione R, Melmed GY, Landers C, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2016;111:1599\u2013607. https:\/\/doi.org\/10.1038\/ajg.2016.298.","journal-title":"Am J Gastroenterol"},{"key":"1939_CR46","unstructured":"Franklin H. Inflammatory bowel disease in patients with psoriasis treated with interleukin-17 inhibitors [Internet]. Drugs in Context. 2020 [cited 2025 July 22]. https:\/\/www.drugsincontext.com\/inflammatory-bowel-disease-in-patients-with-psoriasis-treated-with-interleukin-17-inhibitors\/. Accessed 22 July 2025"},{"key":"1939_CR47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandemeulebroecke M, Reinisch W, Higgins PDR, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693\u2013700. https:\/\/doi.org\/10.1136\/gutjnl-2011-301668.","journal-title":"Gut"},{"key":"1939_CR48","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.3899\/jrheum.100193","volume":"37","author":"K Jenks","year":"2010","unstructured":"Jenks K, Stebbings S, Burton J, Schultz M, Herbison P, Highton J. Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol. 2010;37:2118\u201325. https:\/\/doi.org\/10.3899\/jrheum.100193.","journal-title":"J Rheumatol"},{"key":"1939_CR49","doi-asserted-by":"publisher","unstructured":"Song C, Wang L, Ji X, Wang Y, Hu L, Liu X, et al. Dietary fiber intake influences changes in ankylosing spondylitis disease status. J Clin Med. 2023;12:1621. https:\/\/doi.org\/10.3390\/jcm12041621.","DOI":"10.3390\/jcm12041621"},{"issue":"Suppl 1","key":"1939_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/BF03342649","volume":"15","author":"A Ebringer","year":"1996","unstructured":"Ebringer A, Wilson C. The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. Clin Rheumatol. 1996;15(Suppl 1):62\u20136. https:\/\/doi.org\/10.1007\/BF03342649.","journal-title":"Clin Rheumatol"},{"key":"1939_CR51","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature12721","volume":"504","author":"Y Furusawa","year":"2013","unstructured":"Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446\u201350. https:\/\/doi.org\/10.1038\/nature12721.","journal-title":"Nature"},{"key":"1939_CR52","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.cell.2016.05.041","volume":"165","author":"A Koh","year":"2016","unstructured":"Koh A, De Vadder F, Kovatcheva-Datchary P, B\u00e4ckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165:1332\u201345. https:\/\/doi.org\/10.1016\/j.cell.2016.05.041.","journal-title":"Cell"},{"key":"1939_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12964-023-01219-9","volume":"21","author":"D Zhang","year":"2023","unstructured":"Zhang D, Jian Y-P, Zhang Y-N, Li Y, Gu L-T, Sun H-H, et al. Short-chain fatty acids in diseases. Cell Commun Signaling. 2023;21:212. https:\/\/doi.org\/10.1186\/s12964-023-01219-9.","journal-title":"Cell Commun Signaling"},{"key":"1939_CR54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fcimb.2019.00044","volume":"9","author":"L Yang","year":"2019","unstructured":"Yang L, Liu B, Zheng J, Huang J, Zhao Q, Liu J, et al. Rifaximin alters intestinal microbiota and prevents progression of ankylosing spondylitis in mice. Front Cell Infect Microbiol. 2019;9:44. https:\/\/doi.org\/10.3389\/fcimb.2019.00044.","journal-title":"Front Cell Infect Microbiol"},{"key":"1939_CR55","doi-asserted-by":"publisher","unstructured":"Fukui H. Endotoxin and other microbial translocation markers in the blood: A clue to understand leaky gut syndrome. Cell Mol Med: Open Access [Internet]. iMedPub; 2016 [cited 2025 June 5];3. https:\/\/doi.org\/10.21767\/2573-5365.100023","DOI":"10.21767\/2573-5365.100023"},{"key":"1939_CR56","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","volume":"76","author":"F Ciccia","year":"2017","unstructured":"Ciccia F, Guggino G, Rizzo A, Alessandro R, Luchetti MM, Milling S, et al. Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis. Ann Rheum Dis. 2017;76:1123\u201332. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210000.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR57","doi-asserted-by":"publisher","unstructured":"Zhang Y, Claypool DJ, Ran D, Hou W, Xia Y, Sun J. 175: Virome regulation of intestinal barrier functions depends on the status of vitamin d receptor. Gastroenterology. Elsevier BV; 2025;169:S-45. https:\/\/doi.org\/10.1016\/s0016-5085(25)01061-3","DOI":"10.1016\/s0016-5085(25)01061-3"},{"key":"1939_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508280","volume":"n\/a","author":"C Cai","year":"2025","unstructured":"Cai C, Zheng Y, Sun B, Wang G, Li P, Geng H, et al. Zinc alleviates gut barrier dysfunction by promoting the methylation of AKT. Adv Sci. 2025;n\/a:e08280. https:\/\/doi.org\/10.1002\/advs.202508280.","journal-title":"Adv Sci"},{"key":"1939_CR59","doi-asserted-by":"publisher","DOI":"10.1177\/20503121251330812","volume":"13","author":"HK Min","year":"2025","unstructured":"Min HK, Lee J-Y. Biomarkers for successful tapering of a tumor necrosis factor inhibitor in patients with radiographic axial spondyloarthritis: a pilot study. SAGE Open Med. 2025;13:20503121251330812. https:\/\/doi.org\/10.1177\/20503121251330812.","journal-title":"SAGE Open Med"},{"key":"1939_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15023","volume":"27","author":"A Mathew","year":"2024","unstructured":"Mathew A, Bhagavaldas MC, Biswas R, Biswas L. Genetic risk factors in ankylosing spondylitis: insights into etiology and disease pathogenesis. Int J Rheum Dis. 2024;27:e15023. https:\/\/doi.org\/10.1111\/1756-185X.15023.","journal-title":"Int J Rheum Dis"},{"key":"1939_CR61","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/annrheumdis-2020-eular.2961","volume":"79","author":"M Sagiv","year":"2020","unstructured":"Sagiv M, Slobodin G, Khatib T, Rosner I, Rozenbaum M, Peri R, et al. Ab0119\u2005serum levels of interleukin-22 are high in ankylosing spondylitis, particularly in smokers, but do not correlate with radiographic bone formation nor with disease activity. Ann Rheum Dis. 2020;79:1359\u201360. https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.2961.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR62","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/mr\/roab057","volume":"32","author":"M Kusuda","year":"2022","unstructured":"Kusuda M, Haroon N, Nakamura A. Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches. Mod Rheumatol. 2022;32:484\u201392. https:\/\/doi.org\/10.1093\/mr\/roab057.","journal-title":"Mod Rheumatol"},{"key":"1939_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102902","volume":"20","author":"F Campanaro","year":"2021","unstructured":"Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A. JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis. Autoimmun Rev. 2021;20:102902. https:\/\/doi.org\/10.1016\/j.autrev.2021.102902.","journal-title":"Autoimmun Rev"},{"key":"1939_CR64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s41927-025-00467-1","volume":"9","author":"Q Yao","year":"2025","unstructured":"Yao Q, Zhu Y, Ma Y, Pu Y, Yang X, Zhang Z. Efficacy and safety of upadacitinib, a selective JAK-1 inhibitor in treatment of ankylosing spondylitis: a meta-analysis. BMC Rheumatol. 2025;9:19. https:\/\/doi.org\/10.1186\/s41927-025-00467-1.","journal-title":"BMC Rheumatol"},{"key":"1939_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001042","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, de Vlam K, McInnes IB, Mease PJ, Baer P, Lukic T, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020. https:\/\/doi.org\/10.1136\/rmdopen-2019-001042.","journal-title":"RMD Open"},{"key":"1939_CR66","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004865","volume":"11","author":"Q Dai","year":"2025","unstructured":"Dai Q, Xu A, Ye Y, Lv C, Liu H, Li X, et al. Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial. RMD Open. 2025;11:e004865. https:\/\/doi.org\/10.1136\/rmdopen-2024-004865.","journal-title":"RMD Open"},{"key":"1939_CR67","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","volume":"83","author":"X Baraliakos","year":"2024","unstructured":"Baraliakos X, Deodhar A, van der Heijde D, Magrey M, Maksymowych WP, Tomita T, et al. Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Ann Rheum Dis. 2024;83:199\u2013213. https:\/\/doi.org\/10.1136\/ard-2023-224803.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR68","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1086\/424695","volume":"75","author":"AE Timms","year":"2004","unstructured":"Timms AE, Crane AM, Sims A-M, Cordell HJ, Bradbury LA, Abbott A, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet. 2004;75:587\u201395. https:\/\/doi.org\/10.1086\/424695.","journal-title":"Am J Hum Genet"},{"key":"1939_CR69","doi-asserted-by":"publisher","unstructured":"Schwartzman M, Ermann J, Kuhn KA, Schwartzman S, Weisman MH, EULAR. Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs. RMD Open. 2022. https:\/\/doi.org\/10.1136\/rmdopen-2021-001777.","DOI":"10.1136\/rmdopen-2021-001777"},{"key":"1939_CR70","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard-2023-224916","volume":"83","author":"KL Winthrop","year":"2024","unstructured":"Winthrop KL, Mease P, Kerschbaumer A, Voll RE, Breedveld FC, Smolen JS, et al. Unmet need in rheumatology: reports from the advances in targeted therapies meeting, 2023. Ann Rheum Dis. 2024;83:409\u201316. https:\/\/doi.org\/10.1136\/ard-2023-224916.","journal-title":"Ann Rheum Dis"},{"key":"1939_CR71","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13059-017-1271-6","volume":"18","author":"C Wen","year":"2017","unstructured":"Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis. Genome Biol. 2017;18:142. https:\/\/doi.org\/10.1186\/s13059-017-1271-6.","journal-title":"Genome Biol"},{"key":"1939_CR72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.17305\/bjbms.2016.752","volume":"16","author":"A Duran","year":"2016","unstructured":"Duran A, Kobak S, Sen N, Aktakka S, Atabay T, Orman M. Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis. Biomol Biomed. 2016;16:71\u20134. https:\/\/doi.org\/10.17305\/bjbms.2016.752.","journal-title":"Biomol Biomed"},{"key":"1939_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1480492","author":"Y Ni","year":"2024","unstructured":"Ni Y, Zhong L, Li Y, Zhang Z, Ming B, Qing Y, et al. Exploration of molecular biomarkers in ankylosing spondylitis transcriptomics. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1480492.","journal-title":"Front Immunol"},{"key":"1939_CR74","doi-asserted-by":"publisher","unstructured":"Su Q, Liu Q, Lau RI, Zhang J, Xu Z, Yeoh YK, et al. Faecal microbiome-based machine learning for multi-class disease diagnosis. Nat Commun. 2022;13:6818. https:\/\/doi.org\/10.1038\/s41467-022-34405-3.","DOI":"10.1038\/s41467-022-34405-3"},{"key":"1939_CR75","doi-asserted-by":"publisher","unstructured":"Yu K-H, Beam AL, Kohane IS, Nature Publishing Group. Artificial intelligence in healthcare. Nat Biomed Eng. 2018;2:719\u201331. https:\/\/doi.org\/10.1038\/s41551-018-0305-z.","DOI":"10.1038\/s41551-018-0305-z"},{"key":"1939_CR76","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12891-024-07589-6","volume":"25","author":"S Li","year":"2024","unstructured":"Li S, Chao H, Li Z, Chen S, Zhang J, Hao W, et al. Sex dimorphism of IL-17-secreting peripheral blood mononuclear cells in ankylosing spondylitis based on bioinformatics analysis and machine learning. BMC Musculoskelet Disord. 2024;25:490. https:\/\/doi.org\/10.1186\/s12891-024-07589-6.","journal-title":"BMC Musculoskelet Disord"},{"key":"1939_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13075-021-02484-0","volume":"23","author":"KK Bressem","year":"2021","unstructured":"Bressem KK, Vahldiek JL, Adams L, Niehues SM, Haibel H, Rodriguez VR, et al. Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. Arthritis Res Ther. 2021;23:106. https:\/\/doi.org\/10.1186\/s13075-021-02484-0.","journal-title":"Arthritis Res Ther"},{"key":"1939_CR78","doi-asserted-by":"publisher","unstructured":"Bressem KK, Adams LC, Proft F, Hermann KGA, Diekhoff T, Spiller L, et al. Deep learning detects changes indicative of axial spondyloarthritis at MRI of sacroiliac joints. Radiology. 2022;305:655\u201365. https:\/\/doi.org\/10.1148\/radiol.212526.","DOI":"10.1148\/radiol.212526"},{"key":"1939_CR79","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2025.02.035","author":"T Rozera","year":"2025","unstructured":"Rozera T, Pasolli E, Segata N, Ianiro G. Machine learning and artificial intelligence in the multi-omics approach to gut microbiota. Gastroenterology. 2025. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.035.","journal-title":"Gastroenterology"},{"key":"1939_CR80","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.chom.2025.05.011","volume":"33","author":"KL Greathouse","year":"2025","unstructured":"Greathouse KL, Choudhury A. Precision nutrition and the gut microbiome: harnessing AI to revolutionize cancer prevention and therapy. Cell Host Microbe. 2025;33:766\u201376. https:\/\/doi.org\/10.1016\/j.chom.2025.05.011.","journal-title":"Cell Host Microbe"},{"key":"1939_CR81","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.911","volume":"11","author":"Y-C Zou","year":"2023","unstructured":"Zou Y-C, Wang Z-J, Shao L-C, Xia Z-H, Lan Y-F, Yu Z-H, et al. DNA methylation of DKK-1 may correlate with pathological bone formation in ankylosing spondylitis. Immunity Inflamm Dis. 2023;11:e911. https:\/\/doi.org\/10.1002\/iid3.911.","journal-title":"Immunity Inflamm Dis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01939-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01939-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T02:38:15Z","timestamp":1763433495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01939-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1939"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01939-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"28 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish declaration"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}],"article-number":"12"}}